Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Exclusion Criteria

• •Symptomatic brain metastases
• •Any clinically active cancer, other than SCLC Exception: malignancies with negligible risk of metastases or death (e.g. 5-year OS rate of \>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer. Hormonal therapy for non-metastatic prostate or ductal carcinoma in situ is allowed.
• •Consolidating thoracic radiotherapy. Palliative radiotherapy to the brain or to bones is allowed.
• •History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
• •Any lung disease requiring systemic steroids in doses of \>10 mg prednisolone (or equivalent dose of other steroid).
• •Any serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the trial or interfere with the evaluation of the efficacy and safety of the protocol treatment.
• •Inadequately controlled hypertension, defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>95 mmHg.
• •The patient must be considered stable and hypertension medically controlled.
• •History of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).
• •Prior Reversible Encephalopathy Syndrome (PRES)
• •Severe renal or hepatic impairment.
• •Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
• •Treated with live vaccine within 30 days before enrolment.
• •Hypersensitivity to niraparib or any of its excipients (e.g., tartrazine).
• •Women who are pregnant or in the period of lactation.
• •Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and within the required timelines after last dose of niraparib treatment.
• •Judgment by the investigator that the patient is unlikely to comply with trial procedures, restrictions and requirements.